Mario Basciani
Overview
Explore the profile of Mario Basciani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Intiso D, Basciani M, Santamato A, Intiso M, Di Rienzo F
Toxins (Basel)
. 2015 Jul;
7(7):2454-80.
PMID: 26134256
Pain is a natural protective mechanism and has a warning function signaling imminent or actual tissue damage. Neuropathic pain (NP) results from a dysfunction and derangement in the transmission and...
2.
Basciani M, Di Rienzo F, Bizzarrini M, Zanchi M, Copetti M, Intiso D
Arch Dermatol Res
. 2014 Feb;
306(5):497-503.
PMID: 24522897
Primary palmar hyperhidrosis is a distressing and disabling condition that can produce social, psychological and occupational problems. Although the use of botulinum toxin type A (BoNT-A) has been reported as...
3.
Intiso D, Simone V, Di Rienzo F, Iarossi A, Pazienza L, Santamato A, et al.
NeuroRehabilitation
. 2014 Jan;
34(3):515-22.
PMID: 24473245
Background: Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A). Efficacy and safety of high BoNT-A doses in reducing multi-level spasticity of subjects...
4.
Santamato A, Panza F, Ranieri M, Frisardi V, Micello M, Filoni S, et al.
J Neural Transm (Vienna)
. 2012 Sep;
120(3):469-76.
PMID: 22955957
Botulinum toxin type A (BTX-A) represents the gold standard therapy for focal spasticity after stroke, with low prevalence of complications, reversibility, and efficacy in reducing spastic hypertonia. Current guidelines suggest...
5.
Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D
Dev Med Child Neurol
. 2011 Mar;
53(6):559-64.
PMID: 21413974
Aim: The aim of the present study was to evaluate the efficacy and safety of three doses of botulinum toxin type B (BoNT-B) in reducing persistent sialorrhoea in children with...
6.
Intiso D, Basciani M
J Rehabil Med
. 2009 Nov;
41(13):1100-2.
PMID: 19894009
Background: Pressure sores are a significant secondary complication in spinal cord injured patients. A new indication for botulinum toxin type A is described here, in treatment of recurrent muscular spasms...
7.
Intiso D, Grimaldi G, Russo M, Maruzzi G, Basciani M, Fiore P, et al.
Injury
. 2009 Jun;
41(5):540-3.
PMID: 19524899
Background: Peripheral nerve lesions (PNLs) can complicate the clinical course and outcome of multiply injured patients. Since this often impedes recovery, it can be a significant burden for both patients...
8.
Intiso D, Basciani M, Di Rienzo F, Tolfa M, Grimaldi G, Fiore P
J Rehabil Med
. 2008 Apr;
40(4):315-6.
PMID: 18382829
Objective: Use of botulinum toxin is expanding as clinical studies demonstrate new potential therapeutic applications. In rehabilitation, botulinum toxin is predominantly used as adjunct therapy for the treatment of spasticity,...